Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Accumulated Expenses (2020 - 2026)

Cytek Biosciences filings provide 6 years of Accumulated Expenses readings, the most recent being $23.4 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 9.21% to $23.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.4 million, a 9.21% increase, with the full-year FY2025 number at $23.4 million, up 9.21% from a year prior.
  • Accumulated Expenses hit $23.4 million in Q4 2025 for Cytek Biosciences, up from $20.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $23.4 million in Q4 2025 to a low of $10.8 million in Q3 2021.
  • Median Accumulated Expenses over the past 5 years was $19.6 million (2023), compared with a mean of $18.3 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 68.56% in 2021 and later dropped 20.94% in 2024.
  • Cytek Biosciences' Accumulated Expenses stood at $15.3 million in 2021, then skyrocketed by 38.52% to $21.1 million in 2022, then fell by 5.16% to $20.0 million in 2023, then grew by 7.03% to $21.4 million in 2024, then rose by 9.21% to $23.4 million in 2025.
  • The last three reported values for Accumulated Expenses were $23.4 million (Q4 2025), $20.2 million (Q3 2025), and $21.6 million (Q2 2025) per Business Quant data.